Ultrahuman Acquires viO to Add Advanced Cycle and Ovulation Tracking

Ultrahuman buys viO to bring medical-grade ovulation tracking to Ring AIR

Smart ring maker Ultrahuman announced it has acquired viO HealthTech and is launching Cycle and Ovulation Pro, a new premium plug-in for the Ultrahuman Ring AIR. The move pairs Ultrahuman’s finger-based wearable with viO’s OvuSense temperature algorithm, promising more accurate ovulation confirmation and fertility planning than calendar-based trackers.

Financial terms were not disclosed. Ultrahuman says the algorithm behind the plug-in was developed over 15 years and trained on more than 260,000 cycles collected with medical-grade sensors — a dataset that aims to power clinically informed temperature-based predictions.

Why finger temperature matters: the Ring AIR reads finger-skin temperature continuously, enabling personalized baselines that adapt over time. That gives Cycle and Ovulation Pro the ability to detect shifts like early or late ovulation and confirm ovulation events rather than merely guessing from averages.

Ultrahuman positions this as a more inclusive solution for people whose cycles don’t fit the textbook 28-day model — including those with PCOS, endometriosis, thyroid conditions, or non-bleeding cycles. The company will keep its free Cycle & Ovulation PowerPlug available while offering the Pro plug-in as a $3.99/month or $39.99/year premium feature in core markets.

Features include ovulation confirmation, fertility planning support, detection of atypical patterns, and logs for mood and symptoms to surface long-term wellness trends. For users trying to conceive or managing irregular cycles, confirmation of ovulation — not just prediction — can change decision-making around timing and care.

Real-world impact: imagine a clinician receiving longitudinal, sensor-backed cycle charts rather than single-point patient recall. Or an employer wellness program that can offer individualized reproductive health insights without invasive tests. Those scenarios depend on accurate sensor fusion, validated models, and thoughtful privacy controls.

This acquisition underscores a broader theme: wearables are moving from step counting to clinically relevant biometrics. But bringing medical-grade insights to consumers isn’t just a technical challenge — it touches data governance, regulatory classification, and how outcomes are communicated to users.

• Medical-grade dataset: 260,000+ cycles used to train the algorithm.
• Finger-based continuous temperature improves personalized baselines and ovulation confirmation.
• Designed for diverse cycles: supports users with irregular patterns and medical conditions.
• Commercial rollout: available now as a PowerPlug in the Ultrahuman app across several markets.

What organizations should watch: accuracy claims backed by large datasets are promising, but integration into clinical workflows requires transparent validation and careful user communication. Privacy and consent matter more when data feeds reproductive planning tools.

For product teams, payers, and healthcare providers, the Ultrahuman–viO tie-up is both a signal and a practical capability: signal that wearables aim higher, and capability to deliver temperature-backed cycle insights at scale. The work ahead is technical, regulatory, and human-centered.

QuarkyByte’s approach is to combine rigorous dataset validation, sensor-to-cloud pipeline design, and user-centered outcome mapping so organizations can deploy wearables that deliver clinical value and real-world impact. As wearables evolve, the winners will be those who pair strong models with thoughtful deployment.